Lifetime Fitness launches Clinic Model

As reported in Fitt Insider…

Life Time is stretching its limits.

The latest: The fitness brand’s new medical concept, called MIORA, will offer comprehensive health testing and personalized wellness plans.

  • For $299, patients receive a detailed blood panel, health report, and consultation.

  • A $199 monthly membership includes access to services like peptides, hormone replacement therapy, IV drip, cryotherapy, sauna, red light therapy, and more.

  • Personalized treatment plans will span lifestyle and medical interventions, plus GLP-1s.

The pilot location opens November 27 in its downtown Minneapolis club after soft launching this month.

Why it matters: With Ozempic and Wegovy here to stay, the fitness industry is being forced to adapt. MIORA comes on the heels of Life Time’s plans to offer weight loss prescriptions for members, an effort to encourage GLP-1 users to pair the drugs with long-term lifestyle changes.

Capitalizing even further, Life Time’s clinical offshoot adds holistic medical treatments to the equation — providing care and diagnostics beyond the capacity of gym trainers.

Zooming out: Outmaneuvering traditional healthcare, prevention-focused wellness centers, clinics, and spas are ramping up.

Companies like Restore Hyper Wellness and Pause Studio put recovery first, while Modern Age, Fountain Life, and Serotonin Centers emphasize longevity and anti-aging services.

Punchline: Formerly distinct industries, fitness and wellness have become a package deal. As more people embrace holistic health, expect the overlap of medical, lifestyle, and aesthetic interventions to continue.

Humira Competition Begins

Amjevita, the first biosimilar competitor to Humira hit the U.S. market at the end of January.  Showcasing the dysfunction of our healthcare delivery system, the copycat drug came to market with two drastically different list prices. One, a mere 5% discount relative to Humira and another with a 55% discount. Why two prices and who would pay for the more expensive option?  

The Blockbuster Drug of our Lifetime Loses its Monopoly Status on January 1, 2023

In 2003, a little drug named Humira hit the market under the name DE27. Analysts believed at the time that Humira, which was approved to treat Rheumatoid Arthritis, would eventually generate between $500M and $1B in sales annually. In 2021, Humira’s global sales totaled $20.7B. Lifetime earnings have eclipsed $200B.

Top